DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at $75.00. Patrick Wood has given his Hold rating due to a ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.

Dexcom Chief Commercial Officer Teri Lawver will leave the company as it grapples with challenges following a sales restructuring. Lawver joined the company in January 2023 for the newly created ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

Shares of Dexcom (NASDAQ:DXCM) fell 16% in post-market trading Thursday after the company released its Q3 earnings report which showed only modest topline growth over last year’s quarter.

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

DexCom (NASDAQ:DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly. The continuous glucose ...

The second wave of the medtech industry’s latest earnings season arrives this week, with Boston Scientific, Edwards Lifesciences and Dexcom all set to report their financial results. Johnson & Johnson ...